Navigation Links
NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
Date:8/25/2009

NexBio and the potential efficacy of product candidates that might result from programs that involve substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development activities; decisions by regulatory authorities regarding whether and when to permit the clinical investigation of or approve any drug applications that may result from the programs as well as their decisions regarding labeling and other matters that could affect the commercial potential of product candidates that may result from the program; and competitive developments.


'/>"/>
SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
2. Abbott HIV Test Demonstrates Earlier Disease Detection
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
5. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
6. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
7. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
10. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
11. Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015   InspireMD, Inc. (NYSE ... protection systems, announced today that it will release its full ... 31, 2014 on Thursday, March 12 th after market ... to review its financial results and business outlook. ... ) or (412) 542-4135 (International) and request the InspireMD call. ...
(Date:3/6/2015)... , March 6, 2015 BioSpecifics Technologies ... developing first in class collagenase-based products marketed as XIAFLEX ... U.S. and XIAPEX ®  in the EU, announced today ... audio webcast at 8:30 a.m. ET on Friday, March ... year 2014 financial results and provide a corporate update. ...
(Date:3/6/2015)... March 6, 2015 ... 2011 von der Assistance Publique - Hôpitaux ... Sie ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie ... rekrutiert wurden. Verglichen werden Patienten mit fortgeschrittenem ... Harz-Mikrosphären oder Sorafenib behandelt wurden. Die Ergebnisse ...
(Date:3/5/2015)... 05, 2015 Plant disease specialists from ... at the Annual Meeting of The American Phytopathological Society. ... released online now at APSnet.org/meet . , The ... meeting, to be held August 1-5, 2015 in Pasadena, ... Field Trips, Workshops, and committee meetings, all carefully balanced ...
Breaking Biology Technology:InspireMD to Report Financial Results for the Fourth Quarter and Year Ended December 31, 2014 on Thursday, March 12th 2BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6American Phytopathological Society Announces Annual Meeting Daily Schedule 2
... 15, 2010 Ocera Therapeutics, Inc. announced today ... safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which ...  OCR-002 recently received Orphan Drug status and Fast ... Drug Administration for the treatment of hyperammonemia (excessive ...
... brain-machine interface designed to help paralyzed subjects move objects with ... arm providing sensory feedback, a new study from the University ... into the movement of a computer cursor or an external ... these early systems, vision was the only tool a subject ...
... 2010 The Association for Career and Technical Education ... Role in Worker Retraining" that describes how career and ... adults and providing them the skills needed to re-enter the ... not only focus on local employment needs, but are also ...
Cached Biology Technology:Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy 2Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy 3Robot arm improves performance of brain-controlled device 2Robot arm improves performance of brain-controlled device 3ACTE Releases Issue Brief Outlining Critical Role CTE Plays in Worker Retraining 2
(Date:2/5/2015)... 2015  It is gratifying to see that the ... genomic science as a means to better understand human ... I was honored to participate in today,s White House ... Since the 1980s my teams have ... first sequenced genome of a free living organism, the ...
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... forms far deeper than geologists previously thought, according to new ... of Rice University put very small samples of peridotite, rock ... The scientists found that the rock can and does ... those found as deep as 250 kilometers down in the ...
... conditions lead to what kinds of bacterial infections? If doctors ... pre-treatment with certain kinds of antibiotics. A University of Colorado ... International Journal of Infectious Diseases shows the answer: ... especially prevalent in patients with lung and GI cancers, more ...
... Kan. -- A competitive grant is helping a Kansas ... spreading one of the worst plant diseases into a ... Badillo-Vargas, a plant pathology doctoral student, Puerto Rico, recently ... $71,000 from the U.S. Department of Agriculture,s National Institute ...
Cached Biology News:Magma in Earth's mantle forms deeper than once thought 2Magma in Earth's mantle forms deeper than once thought 3Planning for bacteria in cancer patients may help hospitals fight infections 2USDA grant advancing deadly plant disease, insect research 2
... The product contains 5 ml of ... to release mouse CD4+ T cells from ... isolated mosue CD4+ T cells from Dynabeads ... isolated cells are suitable for any downstream ...
Porcine IFN-gamma ELISpot Development Module...
...
Request Info...
Biology Products: